pink viagra (Photo : REUTERS/BOEHRINGER INGELHEIM/HANDOUT)
The Food and Drug Administration (FDA) will conduct the third analysis for the female libido drug Flibanseri after rejecting it twice previously.
FDA rejected the “Little Pink Pill” because of the concern regarding the pill’s safety for the female population. Advocates of the said pills speculate why the agency is taking too long to approve the Viagra-like drug out there for women, saying that FDA had been long neglecting the issue of women’s sexual disorders.
Flibanserin is the first drug that looked after the sexual issues of women via brain chemistry. It was initially an antidepressant pill to treat the libido problem of women but FDA turned it down due to the lack of effectiveness and the side effects such nausea, dizziness and fatigue, CBS Boston reported.
Researcher said that the pink pill gave women an average of 4.4 satisfying sexual experience per month.
However, doctors said that they already prescribed other antidepressants pills without the approval of FDA to help women with sexual desire disorders. They said that these pills have worse side effect compared to Flibanserin, and it includes seizures and agitation. Dr. James Simon, a gynecologist and one of the researchers for Flibanserin, said that these other antidepressants pills are helpful and it did increase the sexual desire of women, but the side effects are very alarming, according to US News. He added that their study to find the best happy pill for women.
Drugmakers in the past were not successful to produce a Viagra-like pill for women and “Little Pink Pill” can be the answer now.
For the third time, FDA advisory panel will examine again the pill and try to make an assessment regarding it effectiveness and side effects.
